The role of interventional radiology in the management of hepatocellular carcinoma

Current Oncology

Volumn 21, Issue 3, 2014, Pages 480-492

  Molla, N ^a,b   Al Menieir, N ^a   Simoneau, E ^b   Aljiffry, M ^c   Valenti, D ^b   Metrakos, P ^a,b   Boucher, L M ^b   Hassanain, M ^a,b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Ablation; Drug eluting beads; Embolization; Hepatocellular carcinoma; Interventional radiology; Liver biopsy

Indexed keywords

ALBUMIN; BILIRUBIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; IODINE 131; MITOMYCIN; MITOXANTRONE; SORAFENIB; YTTRIUM 90;

ABLATION THERAPY; ARTIFICIAL EMBOLISM; ASCITES; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CRYOABLATION; DRUG ELUTING STENT; ELECTROPORATION; FOLLOW UP; HUMAN; INTERVENTIONAL RADIOLOGY; LASER SURGERY; LIVER BIOPSY; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); MICROWAVE THERAPY; MILD HEPATIC IMPAIRMENT; NONHUMAN; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; RADIATION DOSE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TUMOR SEEDING; TUMOR VOLUME;

EID: 84902674234     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1829     Document Type: Review

References (119)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: globocan 2008. Int J Cancer 2010;127:2893-917.
2. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475-83.
3. Kondo F. Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application: hepatocellular carcinoma. Hepatol Int 2009;3:283-93.
4. Bruix J, Sherman M On behalf of the American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
5. Colecchia A, Scaioli E, Montrone L, et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011; 54: 300-5.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fbrosis in chronic hepatitis C. Hepatology 2003; 38:1449-57.
7. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
8. Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006;125:710-21.
9. Pathi R, Burnes J. Image Guided Liver Biopsy [Web article]. Sydney, Australia: Inside Radiology, Royal Australian and New Zealand College of Radiologists; 2013. [Available at: http://www.insideradiology.com.au/pages/view.php?T_id=85; cited January 17, 2013]
10. Soderstrom CA, McArdle DQ, Ducker TB, Militello PR. The diagnosis of intra-abdominal injury in patients with cervical cord trauma. J Trauma 1983; 23:1061-5.
11. Wee A. Fine needle aspiration biopsy of the liver: algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma. Cytojournal 2005;2:7.
12. Wang P, Meng ZQ, Chen Z, et al. Diagnostic value and complications of fne needle aspiration for primary liver cancer and its infuence on the treatment outcome-a study based on 3011 patients in China. Eur J Surg Oncol 2008;34:541-6.
13. Hertz G, Reddy VB, Green L, et al. Fine-needle aspiration biopsy of the liver: a multicenter study of 602 radiologically guided fna. Diagn Cytopathol 2000;23:326-8.
14. Kuo FY, Chen WJ, Lu SN, Wang JH, Eng HL. Fine needle aspiration cytodiagnosis of liver tumors. Acta Cytol 2004;48:142-8.
15. Edoute Y, Tibon-Fisher O, Ben-Haim SA, Malberger E. Imaging-g uided and nonimaging-guided f ne needle aspiration of liver lesions: experience with 406 patients. J Surg Oncol 1991;48:246-51.
16. Jain D. Diagnosis of hepatocellular carcinoma: fne needle aspiration cytology or needle core biopsy. J Clin Gastroenterol 2002;35(suppl 2):S101-8.
17. Nyman RS, Cappelen-Smith J, Brismar J, von Sinner W, Kagevi I. Yield and complications in ultrasound-guided biopsy of abdominal lesions. Comparison of fne-needle aspiration biopsy and 1.2-mm needle core biopsy using an automated biopsy gun. Acta Radiol 1995;36:485-90.
18. Buscarini L, Fornari F, Bolondi L, et al. Ultrasound-guided fne-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol 1990;11:344-8.
19. Rapaccini GL, Pompili M, Caturelli E, et al. Ultrasound-guided fine-needle biopsy of hepatocellular carcinoma: comparison between smear cytology and microhistology. Am J Gastroenterol 1994;89:898-902.
20. The International Consensus Group for Hepatocellular Neo-plasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658-64.
21. McGahan JP, Bishop J, Webb J, et al. Role of fna and core biopsy of primary and metastatic liver disease. Int J Hepatol 2013;2013:174103.
22. Franca AV, Valerio HM, Trevisan M, et al. Fine needle aspiration biopsy for improving the diagnostic accuracy of cut needle biopsy of focal liver lesions. Acta Cytol 2003;47:332-6.
23. Al Knawy B, Shiffman M. Percutaneous liver biopsy in clinical practice. Liver Int 2007;27:1166-73.
24. Procopet B, Bureau C, Metivier S, et al. Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients. Eur J Gastroenterol Hepatol 2012;24:1209-13.
25. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs A.K. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of hcc. Cancer Treat Rev 2007;33:437-47.
26. Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for hcc before liver transplantation?-No, please don't. J Hepatol 2005;43:563-8.
27. Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, Chen DS. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma-a study based on 420 patients. J Hepatol 1996;25:334-8.
28. Durand F, Regimbeau JM, Belghiti J, et al. Assessment of the benefts and r isk s of percut aneous biopsy before su rgical resection of hepatocellular carcinoma. J Hepatol 2001;35:254-8.
29. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-6.
30. Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transpl 2000;6:67-72.
31. Fornari F, Civardi G, Cavanna L, et al. Complications of ultrasonically guided fne-needle abdominal biopsy. Results of a multicenter Italian study and review of the literature. The Cooperative Italian Study Group. Scand J Gastroenterol 1989;24:949-55.
32. Levy I, Sherman M on behalf of the Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the clip, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;50:881-5.
33. Gadahadh R, Valenti D, Aljiffry M, et al. Surgery and in-terventional radiology collaborate on combination therapy in hepatocellular carcinoma. US Gastroenterol Hepatol Rev 2011;7:44-9.
34. Gervais DA, Goldberg SN, Brown DB, Soulen MC, Mill-ward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009;20(suppl):S342-7.
35. McGahan JP, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990;25:267-70.
36. Lounsberry W, Goldschmidt V, Linke CA, Walder HJ, Chrzan D. The early histologic changes following electrocoagulation. J Urol 1961;86:321-9.
37. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of ef fcacy at explant analysis and of safety for t u mor recu r rence. Liver Transpl 2005;11:1117-26.
38. Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK on behalf of the Interventional Oncology Task Force and Standards Division, Society of Interventional Radiology. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009;20:3-8.
39. Koffron AJ, Auffenberg G, Kung R, Abecassis M. Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 2007;246:385-92.
40. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009;10 4:514-24.
41. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-6.
42. Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381-91.
43. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003;226:441-51.
44. Davis CR. Interventional radiological treatment of hepatocel-lular carcinoma. Cancer Control 2010;17:87-99.
45. Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Effcacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci 2008;5:327-32.
46. Hasegawa K, Makuuchi M, Takayama T, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 2008;49:589-94.
47. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214:761-8.
48. Ng KK, Poon RT, Lam CM, Yuen J, Tso WK, Fan ST. Ef-fcacy and safety of radiofrequency ablation for perivascular hepatocellular carcinoma without hepatic infow occlusion. Br J Surg 2006;93:440-7.
49. Lu DS, Raman SS, Limanond P, et al. Infuence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14:1267-74.
50. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-61.
51. Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology 2007;72(suppl 1):124-31.
52. Ong SL, Gravante G, Metcalfe MS, Strickland AD, Den-nison AR, Lloyd DM. Effcacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review. Eur J Gastroenterol Hepatol 2009;21:599-605.
53. Liu FY, Yu XL, Liang P, Wang Y, Zhou P, Yu J. Comparison of percutaneous 915 MHz microwave ablation and 2450 MHz microwave ablation in large hepatocellular carcinoma. Int J Hyperthermia 2010;26:448-55.
54. Lee K F, Hui JW, Cheung YS, et al. Surgical ablation of hepatocellular carcinoma with 2.45-GHz microwave: a critical appraisal of treatment outcomes. Hong Kong Med J 2012;18:85-1.
55. Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: percutaneous and open approaches. J Surg Oncol 2009;100:619-34.
56. Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation-complications among cohort of 1136 patients. Radiology 2009;251:933-40.
57. Liu Y, Zheng Y, Li S, Li B, Zhang Y, Yuan Y. Percutaneous microwave ablation of larger hepatocellular carcinoma. Clin Radiol 2013;68:21-6.
58. Takami Y, Ryu T, Wada Y, Saitsu H. Evaluation of intraopera-tive microwave coagulo-necrotic therapy (mcn) for hepatocel-lular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci 2013;20:332-41.
59. Permpongkosol S, Nicol TL, Link RE, et al. Differences in ablation size in porcine kidney, liver, and lung after cryoabla-tion using the same ablation protocol. AJR Am J Roentgenol 2007;188:1028-32.
60. Allaf ME, Varkarakis IM, Bhayani SB, Inagaki T, Kavoussi LR, Solomon SB. Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation-initial observations. Radiology 2005;237:366-70.
61. Permpongkosol S, Nicol TL, Khurana H, et al. Thermal maps around two adjacent cryoprobes creating overlapping ablations in porcine liver, lung, and kidney. J Vasc Interv Radiol 2007;18:283-7.
62. Bilchik AJ, Wood TF, Allegra D, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg 2000;135:657-62.
63. Sung GT, Gill IS, Hsu TH, et al. Effect of intentional cryo-injury to the renal collecting system. J Urol 2003;170:619-22.
64. Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1999;23:109-13.
65. Chang XJ, Lu YY, Bai WL, et al. Clinical effcacy and prognostic factors for cryoablation patients with advanced hepatocellular carcinoma [Chinese]. Zhonghua Gan Zang Bing Za Zhi 2011;19:759-63.
66. Chen HW, Lai EC, Zhen ZJ, Cui WZ, Liao S, Lau WY. Ultrasound-guided percutaneous cryotherapy of hepatocel-lular carcinoma. Int J Surg 2011; 9: 188-91.
67. Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013;60:1131-5.
68. Narayanan G. Irreversible electroporation for treatment of liver cancer. Gastroenterol Hepatol (NY) 2011; 7: 313-16.
69. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007;6:307-12.
70. Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford) 2011;13:168-73.
71. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC. Safety and early effcacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013;107:544-9.
72. Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocel-lular carcinoma after percutaneous ethanol injection. Cancer 1996;77:1792-6.
73. Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000;232:665-72.
74. Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embo-lization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-17.
75. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein em-bolization. Arch Surg 2002;137:675-80.
76. Tashiro S, Miyake H, Yoshioka K. The role of portal vein em-bolization prior to hepatic resection for primary and secondary hepatic malignancies. Eur J Clin Med Oncol 2011;3:1-7.
77. Siriwardana RC, Lo CM, Chan SC, Fan ST. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg 2012; 36:1640-6.
78. Simoneau E, Aljiffry M, Salman A, et al. Portal vein embo-lization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) 2012;14: 461-8.
79. Forner A, Trinchet JC. Transarterial therapies in hcc: does embolization increase survival? J Hepatol 2009;51:981-3.
80. Nicolini A, Fasani P, Manini MA, et al. Transarterial emboli-zation with microspheres in the treatment of monofocal hcc. Dig Liver Dis 2009;41:143-9.
81. Chou FI, Fang KC, Chung C, et al. Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 1995;22:379-86.
82. Konno T. Targeting cancer chemotherapeutic agents by use of Lipiodol contrast medium. Cancer 1990;66:1897-903.
83. Gerunda GE, Neri D, Merenda R, et al. Role of transarterial chemoembolization before liver resection for hepatocarci-noma. Liver Transpl 2000;6:619-26.
84. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of hcc. J Hepatol 2012;56(suppl 1):S75-87.
85. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-6.
86. Egawa H, Maki A, Mori K, et al. Effects of intra-arterial chemotherapy with a new lipophilic anticancer agent, estradiol-chlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 1990;44:109-14.
87. Daniels JR, Sternlicht M, Daniels AM. Collagen chemo-embolization: pharmacokinetics and tissue tolerance of cis-diamminedichloroplatinum (ii) in porcine liver and rabbit kidney. Cancer Res 1988;48:2446-50.
88. Bronowicki J P, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994;7 4:16-24.
89. Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (tace) in treatment of hepatocellular carcinoma Hepatogastroenterology 2003;50:183-7.
90. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-9.
91. Malagari K, Alexopoulou E, Chatzimichail K, et al. Trans-catheter chemoembolization in the treatment of hcc in patients not eligible for curative treatments: midterm results of doxorubicin-loaded dc bead. Abdom Imaging 2008;33:512-19.
92. Takayasu K, Arii S, Ikai I, et al. on behalf of the Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830-7.
93. Sumie S, Yamashita F, Ando E, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003;181:1327-34.
94. Lee HS, Kim KM, Yoon JH, et al. Therapeutic effcacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-65.
95. Brown DB, Cardella J F, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embo-lization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009;20(suppl):S219-S26,S26.e1-10.
96. Jelic S, Sotiropoulos GC on behalf of the esmo Guidelines Working Group. Hepatocellular carcinoma: esmo Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v59-64.
97. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-71.
98. Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locore-gional radiological treatment for hepatocellular carcinoma; which, when and how? Cancer Treat Rev 2012;38:54-62.
99. Lewis AL, Gonzalez MV, Lloyd AW, et al. dc bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17: 335-4 2.
100. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: ef fcacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81.
101. Kettenbach J, Stadler A, Katzler IV, et al. Drug-loaded mi-crospheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31:468-76.
102. Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (dc Beads): ct evaluation of response to the treatment. Indian J Radiol Imaging 2013; 23:126-33.
103. Lencioni R, Llovet JM. Modifed recist (m recist) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
104. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the precision v study. Cardiovasc Intervent Radiol 2010;33:41-52.
105. 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004;10(s uppl 1):S107-10.
106. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioem-bolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138:52-64.
107. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-7.
108. Chaudhury PK, Hassanain M, Bouteaud JM, et al. Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization. Curr Oncol 2010;17:67-9.
109. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocel-lular carcinoma. Gastroenterology 2011;140:497-507.
110. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-61.
111. Inarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembo-lization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010;21:1205-12.
112. Gaba RC, Riaz A, Lewandowski RJ, et al. Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol 2010;21:1213-18.
113. Bilbao JI, de Martino A, de Luis E, et al. Biocompatibility, infammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological fndings. Cardiovasc Intervent Radiol 2009;32:727-36.
114. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741-9.
115. Sangro B, Carpanese L, Cianni R, et al. Survival after yt-trium-90 resin microsphere radioembolization of hepatocel-lular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868-78.
116. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747-52.
117. Carretero C, Munoz-Navas M, Betes M, et al. Gastroduode-nal injury after radioembolization of hepatic tumors. Am J Gastroenterol 2007;102:1216-20.
118. Naymagon S, Warner RR, Patel K, et al. Gastroduodenal ul-ceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig Dis Sci 2010;55:2450-8.
119. 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33:919-24.